Santa Clarita-based Specialty Laboratories Inc. reported year-end and fourth-quarter net losses as a result of moving-related costs it experienced in 2004.
“Our high costs this quarter reflect our relocation activities, disposal of some non-productive assets, implementation of certain internal controls ... and a full quarter’s worth of expenses in our new facility,” Specialty’s chief financial officer Kevin R. Sayer said in a statement Thursday. “With our operations now consolidated in the new facility, we expect that Specialty’s cost structure will stabilize and begin to reflect improved efficiencies.”
For the year-end, the laboratory reported a net loss of more than $12 million or 57 cents per share and a net loss of $7.8 million or 34 cents per share for the fourth quarter.
Last summer, Specialty began moving into its recently-constructed three-story 187,262-square-foot office, research and development and laboratory facility on 13.8 acres on Tourney Road.
The firm was formerly divided among four separate buildings in Santa Monica. The company said its facility in Santa Clarita allowed it to consolidate its operations into a single building and increase its available space for future growth and capacity.
For the year-end, the laboratory reported revenues of $134.8 million, compared to revenues of $119.7 million in 2003. For the fourth quarter, the company reported revenue of $35.7 million, compared to revenues of $30.5 million in the same period in 2003.
Specialty is a clinical laboratory for more than 10,000 hospitals and physicians in the United States.
For the fourth quarter 2004, the company reported its testing volume increased 34.4 percent to 844,000. The increase included the company’s temporary independent laboratory business, which accounted for approximately 119,000 tests.
“This was a quarter of successful execution for Specialty,” Sayer said. “We completed our facility relocation ahead of schedule during a quarter when Specialty’s (testing) volumes reached record levels.
“With the challenge of the move now behind us, continued growth is anticipated in 2005 as we focus on the opportunities created by our new contractual relationships with major group purchasing organizations.”
For 2005, Specialty does not anticipate being profitable in the first half of the year, but expects to break-even or show modest profitability during the second half of year.
Shares of Specialty Laboratories held steady at $9.67 on the New York Stock Exchange on Thursday.
